Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances
Research output: Contribution to journal › Article
Authors
Colleges, School and Institutes
External organisations
- Centre for Liver Research, NIHR Birmingham Liver Biomedical Research Unit, University of Birmingham, Birmingham B15 2TT, UK.
Abstract
In 2016, obeticholic acid became the first new licensed therapy for primary biliary cholangitis in >20 years. This therapeutic came at a time of improved disease understanding from biliary and immunological mechanistic insights.
Details
| Original language | English |
|---|---|
| Pages (from-to) | 76-78 |
| Number of pages | 3 |
| Journal | Nature Reviews. Gastroenterology & Hepatology |
| Volume | 14 |
| Issue number | 2 |
| Early online date | 11 Jan 2017 |
| Publication status | Published - Feb 2017 |
Keywords
- obeticholic acid, Primary biliary cholangitis, cholangiocytes, Cholestatic liver disease, biliary